Clinical Research at Georgia Urology

Shaping the Future of Medicine

Clinical research is essential to medical progress, testing new treatments, drugs, and devices to improve patient care. It is a structured process to evaluate new treatments or methods for safety and effectiveness, following strict protocols to protect participants. It brings innovative therapies to patients and advances healthcare, improving outcomes for all. At Georgia Urology, we are committed to conducting safe, impactful studies that help shape the future of medicine.

Phases of Clinical Trials

Phase 1: Tests safety in a small group of people.
Phase 2: Expands testing to a larger group to assess effectiveness.
Phase 3: Compares the new treatment to standard therapies on a larger scale.
Phase 4: Continues monitoring for long-term effects after approval.

Research Transforms Care

Access to New Treatments:
Clinical research allows patients to access new and innovative treatments that are not yet widely available, providing a valuable care option, especially for those with limited treatment alternatives.

Improving Quality of Life:
Many studies focus on treating diseases and enhancing quality of life by managing symptoms and improving patients’ comfort.

Advancing Medical Knowledge:
Research helps healthcare providers understand diseases more deeply, leading to more accurate diagnoses, targeted therapies, and personalized care plans.

Setting New Standards:
Clinical trials contribute to setting new standards of care. Treatments proven effective through research can become part of standard practice, benefiting future patients across the healthcare system.

Faster Innovation in Healthcare:
Clinical research accelerates innovation by exploring the effectiveness of emerging therapies and technologies, bringing the latest advancements directly to patients.

At Georgia Urology, we’re dedicated to achieving these goals through expanding research efforts. Every team member, whether directly involved in studies or supporting our mission in other ways, plays a vital role in advancing patient care and the future of urology. Together, we are all part of this journey, shaping the future of healthcare one study at a time.

Meet Our Research Champions

Our dedicated research team brings expertise, passion, and a commitment to advancing patient care. From conducting studies to ensuring patient safety, our coordinators, investigators, and support staff work tirelessly to bring innovative treatments and impactful findings to life.

Our Clinical Research Coordinators (CRCs) are essential to the success of our studies. They oversee every detail to ensure seamless operations and high-quality care. They are vital in driving our research forward, from patient engagement to data management.

Joan Cruz, CRC
Tina Cagle, CMA, CRC
Cyprian Adi, MD, CRC

We’re excited to expand our research program, with two new studies actively enrolling and two ongoing studies from last year.

Currently Enrolling Studies

Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, the Individual Components of Lidocaine, and Heparin in Subjects with Interstitial Cystitis/Bladder Pain Syndrome – PI: Dr. Proctor
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States – PI: Dr. Canter
Single-Arm, Multi-Center, Prospective Study to Assess the Foramen FinderTM during Peripheral Nerve Evaluation (PNE) – PI: Dr. Capelouto, Sub-I: Dr. Barret-Harlow
Evaluation of the Performance of a Novel Prostate Biopsy System Compared with Standard of Care Biopsy Needle on Quantitative and Qualitative Tissue Parameters – PI: Dr. Proctor

Successfully Completed Studies

Evaluation of Implantable Tibial Neuromodulation (TITAN 2) Pivotal Study – PI: Dr. Proctor
Composur: A Patient-Centric, Phase IV, Open-Label, Prospective, Real-World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder – PI: Dr. Proctor

Upcoming Studies

Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, the Individual Components of Lidocaine, and Heparin in Subjects with Interstitial Cystitis/Bladder Pain Syndrome. – PI: Dr. Proctor
A Noninterventional, Retrospective Multi-Center Study to Evaluate the Effectiveness and Safety of XIAFLEX in Adult Male Participants with Ventral Curvature of the Penis Due to Peyronie’s Disease (RETRO-VC) – PI: Dr. Kapadia
A Phase 2, Randomized, Multi-Center, Open-Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination with Chemotherapy (Gemcitabine and Docetaxel) or Immunotherapy (Pembrolizumab) in Subjects with High-Grade Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer – PI: Dr. Canter

In the Pipeline

An Open-Label, Multicenter Study of Subjects with Metastatic Castrate-Resistant Prostate Cancer Treated with PROVENGE and Boosted with a Single Infusion of Sipuleucel-T to Measure Immune Response – PI: Dr. Canter
WATER IV Prostate Cancer: Aquablation® Therapy versus Radical Prostatectomy for the Treatment of Localized Prostate Cancer – PI: Dr. Kriteman, Co-I: Dr. Gonzalez